Abstract: The present invention relates to a bicistronic expression vector for silencing a gene specifically in astrocytes and neurons, comprising two expression cassettes comprising a first and a second silencer sequence, respectively, wherein the expression of said first silencer sequence within astrocytes is regulated by an astrocyte-specific promoter and the expression of said second silencer sequence within neurons is regulated by a neuron-specific promoter. In a preferred embodiment, said first and second silencer sequences are SOD1 silencer sequences. Pharmaceutical composition comprising said bicistronic vector and the use of the same in the treatment of motoneuron diseases are further described.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: Provided herein is a cell encapsulation device comprising an internal chamber suitable for holding biological agents, wherein the internal chamber is disposed between a first semipermeable layer and a second semi-permeable layer, and the first and second semi-permeable layers are mounted on a supporting frame surrounding a perimeter of the internal chamber; wherein the supporting frame comprises a first frame element and a second frame element, and the first and second frame elements co-operate to position the first and second semipermeable layers at a predetermined separation distance between the layers.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a. variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and uroiithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: Provided herein is a cell encapsulation device comprising an internal chamber suitable for holding biological agents, wherein the internal chamber is disposed between a first semipermeable layer and a second semi-permeable layer, and the first and second semi-permeable layers are mounted on a supporting frame surrounding a perimeter of the internal chamber; wherein the supporting frame comprises a first frame element and a second frame element, and the first and second frame elements co-operate to position the first and second semipermeable layers at a predetermined separation distance between the layers.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Abstract: A synchronization method, a control system and a slave unit for the time synchronization of at least two slave units, in which the slave units and the master unit are connected by two signal lines. A signal transmitted by the master unit returns to the master unit after passing through all the slave units. Two independent counters are provided in each slave unit, these counters being activated by reception of a reference signal transmitted by the master unit. The first time counter counts the time since the receipt of the reference signal via the first signal line and the second time counter counts the time since the receipt of the reference signal via the second signal line. The counter contents are read out as soon as the sum of the counter contents reaches a signal throughput time transmitted previously by the master unit.

Abstract: Collapsible tube head (100, 200, 300, 400) comprising a neck (103, 203, 303, 403) which is fitted, with a port (180, 280, 380, 480) and a shoulder (102, 202, 302, 402). The aforementioned head is fitted with a valve (110, 210, 310, 410) which is inserted in the neck of the said collapsible tube, the said valve comprising a sealing means (112, 212, 312, 412) which is connected to a ring support (115, 215, 315, 415) having an opening (122, 222, 322, 422), the said sealing means being maintained in the closed position of the said opening when the tube is not compressed, and being maintained in the open position when the tube is compressed. The inner surface of the tube is provided with a bore (105, 205, 305, 405) which is disposed close to the base of the said neck. The ring support is fixed to the bore by means of bonding, soldering or force fitting, and the said bore and ring support are preferably provided with complementary connection means, in particular a groove and rice grains.

Abstract: A synchronization method, a control system and a slave unit for the time synchronization of at least two slave units, in which the slave units and the master unit are connected by two signal lines. A signal transmitted by the master unit returns to the master unit after passing through all the slave units. Two independent counters are provided in each slave unit, these counters being activated by reception of a reference signal transmitted by the master unit. The first time counter counts the time since the receipt of the reference signal via the first signal line and the second time counter counts the time since the receipt of the reference signal via the second signal line. The counter contents are read out as soon as the sum of the counter contents reaches a signal throughput time transmitted previously by the master unit.

Abstract: There is a flexible tube having a neck in which an outer surface has a securing attachment and a transverse end wall bearing a cylindrical vent. There is also a rigid end cap having a sealing shirt and a securing skirt having a securing attachment matching that of the neck. The vent of the flexible tube and sealing and securing skirt are arranged so as to obtain longitudinal locking of the rigid end cap on the neck by a simple longitudinal translational movement.

Abstract: A tube provided with a head and a skirt having an orthogonal cross section of particular shape in which the largest inscribed circle has a diameter D. The head, which is designed for fixing of a rigid closure, is provided with a circular cylindrical wall extending towards the inside of the tube and enclosing an orifice concentric to the inscribed circle and having a large diameter, typically more than 0.8D, and takes up substantially the internal volume of the skirt end over a height less than D, preferably less than D/3. The invention is further directed to a closure element, in particular a convenience closure, adapted for fixing substantially irreversibly on the tube head, comprising a base having an external outline matching the shape of the orthogonal cross section of the tube skirt, and a skirt having a diameter in the range of 0.5D to 0.9D.

Abstract: Collapsible tube head (100, 200, 300, 400) comprising a neck (103, 203, 303, 403) which is fitted, with a port (180, 280, 380, 480) and a shoulder (102, 202, 302, 402). The aforementioned head is fitted with a valve (110, 210, 310, 410) which is inserted in the neck of the said collapsible tube, the said valve comprising a sealing means (112, 212, 312, 412) which is connected to a ring support (115, 215, 315, 415) having an opening (122, 222, 322, 422), the said sealing means being maintained in the closed position of the said opening when the tube is not compressed, and being maintained in the open position when the tube is compressed. The inner surface of the tube is provided with a bore (105, 205, 305, 405) which is disposed close to the base of the said neck. The ring support is fixed to the bore by means of bonding, soldering or force fitting, and the said bore and ring support are preferably provided with complementary connection means, in particular a groove and rice grains.